CPA
IMUX icon

Capital Performance Advisors’s Immunic IMUX Stock Holding History

Capital Performance Advisors’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$35 – 1347
2024
Q3 		$35 Buy
+2
New +$28 ﹤0.01% 2829

Other funds holding IMUX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Capital Performance Advisors's IMUX Position: Q4 2024 in Review

Capital Performance Advisors sold out of Immunic (IMUX) in Q4 2024, closing a stake of 2 shares — an estimated $35 sold.

Capital Performance Advisors first reported a position in IMUX in Q3 2024 and held it in 1 quarter. The position peaked at $35 in Q3 2024. 65 funds tracked by Wall St. Rank hold IMUX as of Q4 2024.

  • Capital Performance Advisors reported no remaining Immunic position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 2 Immunic shares in Q4 2024, an estimated $35.
  • Capital Performance Advisors first reported a position in Immunic in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Immunic position peaked at $35 in Q3 2024.
  • 65 funds tracked by Wall St. Rank held Immunic as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.